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Abstract: Pegylated recombinant phenylalanine ammonia lyase (pegvaliase) is an enzyme substitution 
therapy being evaluated for the treatment of phenylketonuria (PKU). PKU is characterized by elevated 
plasma phenylalanine, which is thought to lead to a deficiency in monoamine neurotransmitters and 
ultimately, neurocognitive dysfunction. A natural history evaluation in a mouse model of PKU 
demonstrated a profound decrease in tyrosine hydroxylase (TH) immunoreactivity in several brain 
regions, beginning at 4 weeks of age. Following treatment with pegvaliase, the number of TH positive 
neurons was increased in several brain regions compared to placebo treated ENU2 mice.  
Introduction: PKU is an inborn error of metabolism, caused by a genetic deficiency of phenylalanine 
hydroxylase (PAH), the enzyme responsible for the conversion of phenylalanine (Phe) to tyrosine (Tyr) 
(Scriver et al., 2001). In the absence of PAH, plasma Phe levels are elevated, ultimately leading to 
neurocognitive dysfunction (Al Hafid & Christodoulou, 2015). Neurocognitive dysfunction has also been 
causally linked to reduced plasma Tyr concentrations (de Groot et al., 2010). Pegvaliase (recombinant 
phenylalanine ammonia lyase, rAvPAL: CAS Number 4.3.1.5) is derived from Anabaena variabilis, 
expressed in E.coli and PEGylated. Pegvaliase converts systemic Phe to trans-cinnamic acid and trace 
amounts of ammonia and is currently in clinical development as an enzyme substitution therapy for PKU 
(Sarkissian et al., 2008).  The BTBRPahenu2 (ENU2) mouse model of PKU was developed by germline 
ethylnitrosourea mutagenesis followed by a Phe clearance screen to isolate a mutant mouse line 
deficient in PAH activity (Shedlovsky et al., 1993). The ENU2 mouse model recapitulates many of the 
clinical phenotypes of PKU patients, including hyperphenylalanemia, hypopigmentation, and cognitive 
defects (Shedlovsky et al., 1993). In the ENU2 mouse model, dopamine, catecholamine and serotonin 
concentrations are reduced in multiple brain regions, similar to observations in human PKU patients (de 
Groot et al., 2010). Several hypotheses exist to explain this finding, including competition between Phe 
and Tyr for hydroxylation by TH, reduced synthesis of TH, or reduced BBB transport of Tyr (de Groot et 
al., 2010). Previous studies have demonstrated that chronic administration of pegvaliase to ENU2 mice 
results in normalization of plasma Phe levels, body weight, and fur pigmentation (Sarkissian et al., 2008). 
The objective of the current study was to characterize Tyr expressing neuron populations, astrocytosis, 
and microglial activation in the hypothalamus, midbrain, and pons of untreated ENU2 mice, and then to 
evaluate the effects of pegvaliase on select neuropathological parameters in female ENU2 mice 
following subcutaneous injections given three times weekly for 5, 8 or 12 consecutive weeks.  
Materials and Methods: All experimental procedures were approved by the University of Florida’s 
Animal Care and Use Committee. A natural history study was first conducted on untreated ENU2 mice 
aged 4, 20, 36 and 52 weeks (n= 3-5/age group). Subsequently, forty-four female mice (5-67 weeks old 
at study initiation, weighing 13-36 grams), consisting of 29 ENU2 mice and 15 wild type (WT) control 
mice were assigned to 9 groups (5 mice/group) and administered a bolus injection of either placebo 
vehicle or pegvaliase three times per week (Monday, Wednesday, Friday) for 5, 8, or 12 weeks. Body 
weights were recorded for all animals pre-study and prior to dose administration for the duration of the 
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study. Blood samples for Phe analysis were obtained at 4 pm on pre-study and Study Days 7, 14, 28, 42, 
and 70 by nicking the tail vein. Plasma Phe was determined using a modified fluorimetric assay 
(McCaman & Robins, 1962). To survey the survival of dopaminergic neurons and to assess the degree of 
astrocytic and microglial activation, a one in six series of sections was immunohistochemically stained 
for the TH (PV), glial fibrillary associated protein (GFAP, astrocytes), or the microglial markers CD68 and 
Iba-1 via previously published protocols (Kielar et al., 2007, Macauley et al., 2012; Vuillemenot et al., 
2015; Weimer et al., 2007). To visualize neuronal cytoarchitecture and permit stereological analyses of 
total neuron number, a one in six series of 40 µm coronal sections from each forebrain was mounted 
onto gelatin-chrome alum coated microscope slides and Nissl stained with cresyl fast violet (Kielar et al., 
2007).  
Results: In the natural history study, optical fractionator estimates of the number of TH positive neurons 
in the arcuate nucleus, dorsomedial hypothalamic nucleus and area A8 of the pontine reticular 
formation in WT and untreated ENU2 mice at 4, 20, 36, and 52 weeks of age revealed a significant 
reduction in the number of TH positive neurons in all three types of nuclei, beginning at 4 weeks of age 
in untreated ENU2 mice. In marked contrast, counts of Nissl stained neurons in the same brain nuclei 
revealed no significant change in the number of stained neurons in any nuclei at any age. Staining for 
glial fibrillary associated protein (GFAP) as a marker of astrocytosis or CD68 as a marker for microglial 
activation revealed no obvious differences between WT and untreated ENU2 mice at any age. 
Immunostaining for Iba-1 as an additional marker for microglial activation revealed only subtle 
differences in microglial morphology, with microglia appearing slightly more darkly stained and with a 
marginally larger cell body than seen in WT mice at 9 and 13 months of age. However, thresholding 
image analysis determined these differences in Iba-1 staining were not significant at either age.  
In the subsequent study, pegvaliase treatment was well tolerated for the duration of the study, and 
treated animals had a sleek and healthy appearance, with a fur coat that returned to the dark color of 
the WT background strain. In contrast, untreated ENU2 mice maintained the characteristic hypo-
pigmented coat, and unhealthy appearance associated with PAH deficiency. Plasma phenylalanine 
decreased in treated mice within the first 7 days of treatment. A probable immune response was 
observed at approximately day 14, as evidenced by increasing plasma phenylalanine levels. Upon 
tolerization, plasma Phe returned to levels similar to WT animals by approximately Day 28, and 
remained at or below WT levels for the remainder of the treatment period. Following treatment with 
pegvaliase for 5, 8, or 12 weeks, optical fractionator counts obtained from the arcuate nucleus and 
dorsomedial hypothalamic nucleus revealed a significant increase in the number of TH positive neurons 
compared to placebo treated mice (Figure 1).  
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Figure 1: Effects of pegvaliase upon immunohistochemically detectable tyrosine hydroxylase (TH) in 
ENU2 mice. (A) Compared to 12 week old wild type mice (WT), staining for the dopaminergic marker 
tyrosine hydroxylase (TH) revealed markedly less intense TH immunostaining in the arcuate nucleus 
(ARC) and dorsomedial hypothalamic nucleus (DMN) age-matched ENU2 mutant mice, together with an 
apparent decrease in the number of neurons in both nuclei. In pegvaliase treated ENU2 mice of the 
same age the intensity of TH staining was largely restored, although not to the levels seen in control WT 
mice. Scale bar = 200 µm. (B) Optical fractionator counts of TH stained neurons in these nuclei 
confirmed there to be a significant reduction in both ARC and DMN in untreated ENU2 compared to WT 
control mice at all ages examined. This phenotype was partially reversed by 5-12 weeks of pegvaliase 
treatment, which significantly increased the number of neurons in both nuclei, albeit not to WT levels.  
Discussion: The natural history assessments in untreated ENU2 mice revealed a dramatic and early 
onset downregulation of TH in multiple brain areas of ENU2 mice, accompanied by subtle microglial 
activation. This finding is consistent with reports implicating monoamine neurotransmitter deficiency as 
A 
B 
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partially responsible for the neurocognitive symptoms commonly observed in PKU. Although the 
particular mechanism of neurotransmitter deficiency has not been fully elucidated, it is generally 
accepted to be the result of chronically elevated Phe in PKU patients and may be the result of 
competition between Phe and Tyr for hydroxylation by TH, reduced synthesis of TH, or reduced BBB 
transport of Tyr (de Groot et al., 2010; Harding, 2014).  Nissl staining of neurons in untreated mice in the 
natural history study indicated that TH expressing neurons are still present in the brain, but have simply 
downregulated TH expression to the point that they are no longer detectable by immunostaining. As 
such these cells may be amenable to intervention, and the therapeutic effects of pegvaliase upon TH 
neuron number suggest that this is the case. As expected given the dramatic reduction in plasma Phe, 
treatment with pegvaliase resulted in a significant increase in TH positive neurons. The mechanism by 
which pegvaliase influences TH levels is currently unclear, and needs further investigation. This effect is 
observed after 5 weeks of treatment with pegvaliase, and is maintained during 12 weeks of treatment. 
Although the effect of pegvaliase did not fully restore TH positive neurons to WT levels, the data 
indicates that pegvaliase is capable of rescuing TH deficiency in ENU2 mice within the first 5 weeks of 
treatment, and can maintain this effect throughout long-term treatment. Given that the reduction in TH 
staining occurs to a similar extent in ENU2 mice irrespective of age, our data suggest that rather than 
there being a therapeutic window of opportunity, pegvaliase treatment may have therapeutic efficacy 
across a broad age range. It will be important to test this hypothesis experimentally.  
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Highlights of Manuscript MGM_2017_97 
 
 Phenylketonuria (PKU) is characterized by neurocognitive dysfunction 
 
 Pegvaliase, an enzyme substitution therapy, may potentially treat PKU 
 
 Pegvaliase administration largely reversed dopaminergic deficits in PKU mice 
 
 Pegvaliase may have therapeutic efficacy across a broad age range 
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